RxDoctor Payments Data

Bryan Metzger, OD

Optometrist · Alexandria, KYNPI 1982294559

Payments from drug & device makers

$1,188in general payments, 2019–2025

Across 25 payments — averaging $47.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sun Pharmaceutical Industries Inc.$305
  • Bausch & Lomb Americas Inc.$266
  • Tarsus Pharmaceuticals, Inc.$191
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$125
  • Harrow Eye, LLC$121
  • Alcon$83
  • plus $97 from 2 others

What the payments were for

  • Food & beverage$1,188100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,188 in reported general payments places this provider in the 60th percentile of 712 optometrist providers in Kentucky.

See all optometrist providers in Kentucky

Medicare billing

Part B allowed, 2024
$37,418
Medicare patients
234
Services billed
672

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine60$59,758
XiidraLifitegrast33$50,809
TyrvayaVarenicline Tartrate23$17,480
LumiganBimatoprost15$6,964
Prednisolone Acetate70$2,187
Latanoprost127$1,301
Difluprednate11$843
Timolol Maleate50$509
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat19$299
Brimonidine Tartrate38$257

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan$44$66,72275 claims
Bausch & Lomb Americas Inc.Xiidra$266$50,80933 claims
Oyster Point Pharma, Inc.Tyrvaya$53$17,48023 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 712 optometrist providers in Kentucky.

Other optometrist in Alexandria

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →